UnknownPhase 2NCT01361763
Safety Study of Dabigatran in CADASIL
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- S. Andrea Hospital
- Principal Investigator
- Francesco Orzi, MDNESMOS Department, University of Rome "La Sapienza"; St. Andrea Hospital
- Intervention
- Dabigatran(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2015
Study locations (2)
- Emergency Department Stroke Unit, Umberto I Hospital, Rome, Rome, Italy
- NESMOS Department St. Andrea Hospital, Rome, Rome, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01361763 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05755997CERebrolysin In CADASILEver Neuro Pharma GmbH
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT05072483Natural History Study of CADASILNational Heart, Lung, and Blood Institute (NHLBI)